Literature DB >> 3057923

Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder.

M T Pato1, R Zohar-Kadouch, J Zohar, D L Murphy.   

Abstract

To evaluate the need for maintenance drug therapy in patients with obsessive-compulsive disorder, the authors assessed 21 patients with obsessive-compulsive disorder who manifested sustained improvement during 5 to 27 months of clomipramine treatment and who agreed to participate in a double-blind discontinuation study. Of 18 patients who completed the study, 16 had substantial recurrence of obsessive-compulsive symptoms by the end of the 7-week placebo period. In addition, 11 had a significant increase in depressive symptoms. Treatment duration before discontinuation of clomipramine was not related to the frequency or severity of obsessive-compulsive or depressive symptom appearance. These findings suggest that prolonged drug treatment may be warranted for obsessive-compulsive disorder.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3057923     DOI: 10.1176/ajp.145.12.1521

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  21 in total

Review 1.  Obsessive compulsive disorder.

Authors:  G Mustafa Soomro
Journal:  BMJ Clin Evid       Date:  2012-01-18

2.  Intensive Family-Based Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder: Applications for Treatment of Medication Partial- or Nonresponders.

Authors:  Wendi E Marien; Eric A Storch; Gary R Geffken; Tanya K Murphy
Journal:  Cogn Behav Pract       Date:  2009-08

3.  Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial.

Authors:  Michael Rufer; Iver Hand; Heike Alsleben; Anne Braatz; Jürgen Ortmann; Birgit Katenkamp; Susanne Fricke; Helmut Peter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

4.  Unified protocol for the discontinuation of long-term serotonin reuptake inhibitors in obsessive compulsive disorder: Study protocol and methods.

Authors:  Christina L Boisseau; Steven A Rasmussen
Journal:  Contemp Clin Trials       Date:  2018-01-03       Impact factor: 2.226

Review 5.  A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.

Authors:  L L Carpenter; C J McDougle; C N Epperson; L H Price
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

Review 6.  Treatment of obsessive-compulsive disorder in children and adolescents. A review of the literature.

Authors:  P H Thomsen
Journal:  Eur Child Adolesc Psychiatry       Date:  1996-06       Impact factor: 4.785

Review 7.  How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems.

Authors:  Dennis L Murphy; Meredith A Fox; Kiara R Timpano; Pablo R Moya; Renee Ren-Patterson; Anne M Andrews; Andrew Holmes; Klaus-Peter Lesch; Jens R Wendland
Journal:  Neuropharmacology       Date:  2008-09-11       Impact factor: 5.250

Review 8.  Current concepts in the pharmacological treatment of obsessive-compulsive disorder.

Authors:  J Zohar; R C Zohar-Kadouch; S Kindler
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

Review 9.  Eating disorder and obsessive-compulsive disorder: neurochemical and phenomenological commonalities.

Authors:  J L Jarry; F J Vaccarino
Journal:  J Psychiatry Neurosci       Date:  1996-01       Impact factor: 6.186

Review 10.  Anxiety disorders. Focus on obsessive-compulsive disorder.

Authors:  L Warneke
Journal:  Can Fam Physician       Date:  1993-07       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.